NEW YORK, Feb. 26, 2021 (Globe NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a business-phase pharmaceutical company targeted on the health safety current market, today declared that management will host a webcast and conference contact to provide a business update at 4:30 P.M. ET on Thursday, March 4, 2021. Taking part on the get in touch with will be Dr. Phil Gomez, Main Executive Officer, Daniel Luckshire, Chief Monetary Officer, and Dr. Dennis Hruby, Chief Scientific Officer.
A stay webcast of the simply call will be offered on the Firm’s web-site at www.siga.com beneath the ‘Events & Presentations’ tab in the Trader Relations section, or by clicking right here. Participants may also obtain the simply call by dialing 877-407-6184 for domestic callers or 201-389-0877 for intercontinental callers. You should log in roughly 5-10 minutes prior to the scheduled start out time.
A replay of the simply call will be obtainable for two weeks by dialing 877-660-6853 for domestic callers or 201-612-7415 for international callers and applying Convention ID: 13715918. The archived webcast will be out there in the Events and Presentations area of the company’s website.
ABOUT SIGA Technologies, INC. and TPOXX®
SIGA Systems, Inc. is a industrial-stage pharmaceutical enterprise targeted on the wellbeing safety marketplace. Overall health stability comprises countermeasures for organic, chemical, radiological and nuclear attacks (biodefense sector), vaccines and therapies for rising infectious diseases, and health and fitness preparedness. Our direct item is TPOXX®, also recognised as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment method of human smallpox disorder induced by variola virus. TPOXX is a novel tiny-molecule drug and the US maintains a stockpile of 1.7 million oral courses in the Strategic Nationwide Stockpile less than Job BioShield. The oral formulation of TPOXX was permitted by the Food and drug administration for the procedure of smallpox on July 13, 2018. In September 2018, SIGA signed a deal with Biomedical Superior Exploration and Growth Authority (BARDA) for supplemental procurement and improvement related to both equally oral and intravenous formulations of TPOXX. For extra data about SIGA, you should go to www.siga.com.
Smallpox is a contagious, disfiguring and normally fatal illness that has impacted humans for countless numbers of yrs. Naturally taking place smallpox was eradicated globally by 1980, the consequence of an unprecedented worldwide immunization marketing campaign. Samples of smallpox virus have been saved for research functions. This has led to concerns that smallpox could sometime be utilized as a biological warfare agent. A vaccine can protect against smallpox, but the chance of the existing vaccine’s side outcomes is far too substantial to justify routine vaccination for folks at minimal possibility of exposure to the smallpox virus.
This push launch is made up of particular “forward-wanting statements” in just the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-hunting statements are matter to several regarded and unfamiliar dangers and uncertainties, and SIGA cautions you that any forward-searching facts offered by or on behalf of SIGA is not a ensure of long run overall performance. Much more detailed info about SIGA and possibility components that may well have an impact on the realization of forward-seeking statements, together with the forward-seeking statements in this push release, is set forth in SIGA’s filings with the Securities and Trade Fee, which includes SIGA’s Yearly Report on Kind 10-K for the fiscal year finished December 31, 2020, and in other files that SIGA has submitted with the SEC. SIGA urges investors and safety holders to go through those documents cost-free of demand at the SEC’s world-wide-web site at http://www.sec.gov. Intrigued events may well also attain people paperwork no cost of cost from SIGA. Forward-searching statements are latest only as of the date on which this sort of statements had been produced, and apart from for our ongoing obligations under the United States of The usa federal securities rules, we undertake no obligation to update publicly any ahead-seeking statements whether as a outcome of new information, long term occasions, or otherwise.
The facts contained in this push release does not automatically replicate the posture or the plan of the Authorities and no formal endorsement should be inferred.
1 http://www.mayoclinic.org/conditions-ailments/smallpox/fundamental principles/definition/con-20022769
Make contact with: Call: Daniel J. Luckshire 212-672-9100 [email protected]